Results 221 to 230 of about 38,575 (293)

Proprotein Convertase Subtilisin/Kexin Type 9 Induction in COVID-19 Is Poorly Associated with Disease Severity and Cholesterol Levels. [PDF]

Infect Dis Rep
Mester P, Amend P, Schmid S, Wenzel JJ, Höring M, Liebisch G, Krautbauer S, Müller M, Buechler C, Pavel V.   +9 more
europepmc   +1 more source

The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis. [PDF]

Front Cardiovasc Med
Liu D, Zhang J, Zhang X, Jiang F, Wu Y, Yang B, Li X, Fan X, Li H, Sun Y, Gou R, Wang X.   +11 more
europepmc   +1 more source

Maternal Obesity Modulates Cord Blood Concentrations of Proprotein Convertase Subtilisin/Kexin-type 9 Levels. [PDF]

J Endocr Soc
Rallis D, Papathanasiou AE, Christou H.
europepmc   +1 more source

Phenotypic homozygous familial hypercholesterolemia successfully treated with proprotein convertase subtilisin/kexin type 9 inhibitors. [PDF]

Clin Case Rep
Tani R, Matsunaga K, Toda Y, Inoue T, Fu HY, Minamino T.   +5 more
europepmc   +1 more source

Expression of pro- and anti-inflammatory cytokines during anti-proprotein convertase subtilisin/kexin type 9 therapy in patients with statin-resistant familial hypercholesterolemia. [PDF]

Front Cardiovasc Med
Morales-Portano JD, Trujillo-Cortés R, Roa-Martínez BM, Pérez-Cabeza de Vaca R, García S, Mondragón-Terán P, Suárez-Cuenca JA.   +6 more
europepmc   +1 more source

Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis. [PDF]

BMC Cardiovasc Disord
Hosseini K, Soleimani H, Maleki S, Nasrollahizadeh A, Tayebi S, Nelson J, Heffron SP.   +6 more
europepmc   +1 more source

Proprotein convertase subtilisin/kexin type 9 inhibitors protect against contrast-associated acute kidney injury in patients with atherosclerotic cardiovascular disease. [PDF]

Front Cardiovasc Med
Ma Y, Fan H, Mi W, Ma J, Deng Y, Song Y, Li X.   +6 more
europepmc   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients Following Acute Coronary Syndromes: From Lipid Lowering and Plaque Stabilization to Improved Outcomes. [PDF]

J Clin Med
Dimitriadis K, Pyrpyris N, Iliakis P, Beneki E, Adamopoulou E, Papanikolaou A, Konstantinidis D, Fragkoulis C, Kollias A, Aznaouridis K, Tsioufis K.   +10 more
europepmc   +1 more source

Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection. [PDF]

Microb Cell Fact
Muzammil K, Hooshiar MH, Varmazyar S, Omar TM, Karim MM, Aadi S, Kalavi S, Yasamineh S.   +7 more
europepmc   +1 more source